Israeli Cannabis Producer Touts Record Q3 Revenue, Gross Profit Increase

InterCure Ltd. INCR INCR INCR, which is doing business as Canndoc, announced on Tuesday its financial and operating results for the third quarter ended September 30, 2022.

"We continued to execute on our international expansion plans building our footprint organically and exploring strategic acquisitions in key markets to meet the solid demand for our high-quality branded products," Alexander Rabinovitch, the company's CEO, said. "We expect 2022 to be another milestone year for InterCure, solidifying our leadership position in the pharmaceutical cannabis market."

Q3 2022 Financial Highlights

  • Record revenue of CA$39 million ($29.4 million), representing a 63% growth in the third quarter of 2021 and representing sequential growth of 6%.
  • Gross profit totaled CA$17.06 million, compared to $CA9.55 million in the prior year's period.
  • The gross profit margin was 44%, compared to 40% in the same quarter of last year.
  • Adjusted EBITDA increased 85% year-over-year to CA$9 million, representing 22% of revenues.
  • The adjusted EBITDA margin was 22%, compared to 19% in the corresponding quarter of 2021.
  • General and administrative expenses totaled $CA5.4 million, while marketing and selling expenses were roughly CA$6.5 million.

Q3 2022 Operational Highlights

  • Record of new product launches with more than 10 new GMP SKUs added to the company's portfolio of products during the quarter.
  • Expansion of the company's medical cannabis dedicated pharmacy chain to a total of 25 locations as of the end of the third quarter.
  • Continued scaling up production cultivation and production of the Southern facility as the region's largest and most advanced facility of its kind.

Price Action

InterCure's shares traded 4.55% lower at $5.25 per share at the time of writing on Tuesday.

Related News

Photo: Courtesy of micheile dot com on Unsplash

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: CannabisEarningsNewsMarketsAlexander RabinovitchCanndocfinancial reportisraelmarijuanapremiumthird quarter results
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Cannabis is evolving – don’t get left behind!

Curious about what’s next for the industry and how to leverage California’s unique market?

Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!

Get your tickets now to secure your spot and avoid last-minute price hikes.